[Management of adverse events induced by TNFalpha blocking agents].
TNFalpha blocking agents are effective and essential tools in the management of many inflammatory conditions including rheumatoid arthritis, spondylarthropathies and chronic inflammatory bowel disease. With time, some known side-effects have gained in importance and others have appeared. This article focuses on the potential risks of infection and autoimmunity induced by TNFalpha blocking agents and on the strategy to prevent and treat such adverse events.
Service d'immunologie et allergie, CHUV, 1011 Lausanne. samuel.chappuis@chuv.ch
S
S
Chappuis
C
C
Ribi
F
F
Spertini
D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001327:Autoimmune Diseases / Q000139:chemically induced / Q000628:therapy; D064420:Drug-Related Side Effects and Adverse Reactions / Q000628:therapy*; D006801:Humans; D007239:Infections / Q000139:chemically induced / Q000453:epidemiology / Q000209:etiology; D009369:Neoplasms / Q000139:chemically induced / Q000628:therapy; D012307:Risk Factors; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha